ArticleEJHaem2024

Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy.

Nicole Lamanna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.